Literature DB >> 8340063

Activin induces cell death in hepatocytes in vivo and in vitro.

R H Schwall1, K Robbins, P Jardieu, L Chang, C Lai, T G Terrell.   

Abstract

While studying endocrine responses to activin in female rats, we discovered that activin caused a marked reduction in liver mass. The regressed livers exhibited no gross signs of necrosis or infarction, but histopathological evaluation revealed extensive cell death in the centrilobular regions. The dying cells appeared to fragment into structures resembling apoptotic bodies. Liver mass and histological appearance were restored after cessation of activin infusion, indicating that on an organ level, this effect was reversible. To determine whether the effects observed in vivo were caused by direct actions on the liver, we then tested activin on isolated hepatocytes in serum-free medium. Under these conditions, activin caused many hepatocytes to undergo fragmentation, which was accompanied by a loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-reducing activity, an index of viability. We compared the effects of activin with those of transforming growth factor-beta because activin is structurally related to transforming growth factor-beta and because transforming growth factor-beta has been shown previously to induce cell death in hepatocytes. Both proteins caused cell death of comparable magnitude, as defined by the extent of loss of MTT-reducing activity, but transforming growth factor-beta was active at one tenth of the effective activin concentrations. A neutralizing monoclonal antibody to transforming growth factor-beta blocked the response to transforming growth factor-beta but had no effect on the response to activin. Conversely, follistatin, an activin-binding protein, blocked the response to activin but not to transforming growth factor-beta. Inhibin, which antagonizes the effects of activin in many systems, had little effect on the response to activin. Activin and transforming growth factor-beta differed in their onset of action; exposure to transforming growth factor-beta for only 1 hr induced a maximal response, whereas maximal response to activin required its continuous presence for 24 hr. These results show a novel effect of activin on cell death in hepatocytes in vivo and in vitro, suggesting that activin may have a previously unrecognized role in regulating hepatic function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340063     DOI: 10.1016/0270-9139(93)90018-i

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

Review 1.  Apoptosis.

Authors:  S Afford; S Randhawa
Journal:  Mol Pathol       Date:  2000-04

2.  Expression changes of activin A in the development of hepatic fibrosis.

Authors:  X Huang; D G Li; Z R Wang; H S Wei; J L Cheng; Y T Zhan; X Zhou; Q F Xu; X Li; H M Lu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Authors:  M Leist; F Gantner; G Künstle; I Bohlinger; G Tiegs; H Bluethmann; A Wendel
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

Review 4.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

5.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.

Authors:  Zhenhua Wang; Ning Zhang; Ruifeng Song; Ruitai Fan; Liuqin Yang; Liping Wu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

Review 6.  Understanding the marvels behind liver regeneration.

Authors:  Anan Abu Rmilah; Wei Zhou; Erek Nelson; Li Lin; Bruce Amiot; Scott L Nyberg
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-03-28       Impact factor: 5.814

7.  Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin A.

Authors:  Yosif Manavski; Tobias Abel; Junhao Hu; Dina Kleinlützum; Christian J Buchholz; Christina Belz; Hellmut G Augustin; Reinier A Boon; Stefanie Dimmeler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-27       Impact factor: 11.205

8.  Activin A and follistatin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Georgios Α Triantafyllou; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-07-25       Impact factor: 8.694

9.  Tob1 is a constitutively expressed repressor of liver regeneration.

Authors:  Karen J Ho; Nhue L Do; Hasan H Otu; Martin J Dib; Xianghui Ren; Keiichi Enjyoji; Simon C Robson; Ernest F Terwilliger; Seth J Karp
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

Review 10.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.